Table 3.
Log-rank tests and Cox regression analysis of factors associated with OS.
| Parameters | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| P | HR | 95% CI | P | |
| Gender | ||||
| Female vs Male | 0.563 | |||
| Age (years) | ||||
| ≥60 vs <60 | 0.339 | |||
| Smoke | ||||
| Yes vs No | 0.758 | |||
| Tumor location | ||||
| Left lung vs Right lung | 0.027 | 1.675 | 1.036–2.707 | 0.035 |
| BM | ||||
| Yes vs No | 0.011 | 1.266 | 0.743–2.156 | 0.386 |
| Time from initial treatment to radiotherapy (months) | ||||
| >3 vs ≤3 | 0.076 | 1.249 | 0.719–2.171 | 0.431 |
| Cycle of chemotherapy before radiotherapy | ||||
| >4 vs ≤4 | 0.254 | |||
| Cycle of chemotherapy before BM | ||||
| >5 vs ≤5 | 0.715 | |||
| CCRT | ||||
| No vs Yes | 0.037 | 1.450 | 0.860–2.444 | 0.163 |
| RT dose (Gy) | ||||
| ≤52.5 vs >52.5 | 0.791 | |||
| T | ||||
| Tx vs T2–4 vs T1 | 0.261 | |||
| N | ||||
| N2–3 vs N0–1 | 0.551 | |||
| SII | ||||
| >937.3 vs ≤937.3 | 0.025 | 2.212 | 0.872–5.616 | 0.095 |
| MLR | ||||
| ≤0.12 vs >0.12 | 0.106 | 2.076 | 1.168–3.689 | 0.013 |
| NLR | ||||
| >3.23 vs ≤3.23 | 0.132 | 1.063 | 0.482–2.346 | 0.880 |
| PLR | ||||
| ≤97.3 vs >97.3 | 0.162 | 1.311 | 0.765–2.249 | 0.324 |
| PNI | ||||
| >51.4 vs ≤51.4 | 0.966 | |||
| PAR | ||||
| ≤4.38 vs >4.38 | 0.619 | |||
OS, overall survival; HR, hazards ratio; CI, 95% confidence interval; BM, brain metastasis; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; SII, systemic immune-inflammation index; MLR, monocyte–lymphocyte ratio; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte radio; PNI, prognostic-nutrition index; PAR, platelet–albumin ratio.